Cancer
Cancer remains a significant health concern in the United States, with an estimated 1.8 million new cases and 606,520 deaths expected in 2021. The most common types of cancer in the US are breast, lung, prostate, and colorectal. While cancer death rates have been declining over the past few decades, disparities in cancer incidence and mortality persist among different racial and ethnic groups and geographic regions. Advances in cancer research and treatment continue to offer for improved outcomes and quality of life for those affected by this. canZero strives to be part of this endeavor!
Traditional therapy of tumors includes chemotherapy, radiation, and surgery. However, mortality rates still range between 10% and 95% for those treatment modalities. It is important to explore alternative treatments and therapies to improve the chances of successful treatment and recovery.
canZero proposes a new immunotherapy strategy that utilizes personalized cancer immunodrugs. This approach offers several potential advantages, including systemic treatment, prevention of recurrence, cost-effectiveness, and high flexibility in design. We believe that this strategy could be a gamechanger in the fight against cancer.
canZero’s SAPNs as Vaccines
Self-assembling protein nanoparticles (SAPNs) are a promising tool for vaccine development. With their viral-like size and shape, SAPNs can effectively present antigens and contain immunostimulatory molecules, eliminating the need for admixed adjuvants. Additionally, SAPNs allow for refined and targeted vaccine development, and new SAPNs can be rapidly produced for each different type of cancer, or personalized medicine. A malaria SAPN has already successfully completed a phase I clinical trial, highlighting the potential of this technology.
canZero’s SAPNs as Drug Delivery Devices
In addition to the applications as vaccines, canZero's SAPNs offer also various efficient ways to encapsulate cancer drug molecules such as CpG, which enhances tumor antigen presentation and T cell response. Furthermore, SAPNs can be covalently linked to cancer drugs with almost 100% coupling efficiency, making them a valuable tool in cancer treatment.
canZero’s Unique VaccinoDrug Technology
SAPNs are a highly potent vaccine that can further be loaded with CpG to enhance tumor antigen presentation and T cell response for cancer treatment. They can also be used as drug delivery devices by covalently coupling specific cancer drugs to them. With a rapid production time of only 37 hours, SAPNs are an efficient platform for personalized medicine. The combination of the vaccine with drug targeting and delivery makes canZero’s SAPNs a very unique VaccinoDrug platform (see our current pipeline). Overall, canZero's SAPNs represent a unique VaccinoDrug platform that combines the benefits of vaccines with drug targeting and delivery.
